Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This indicates a site software/version update for the ClinicalTrials.gov page, with no evident changes to the study's details or eligibility criteria.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe study page’s footer revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than a change to the trial information itself.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision badge updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check104 days agoChange DetectedMinor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.